# Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

> **NCT00891371** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 42 (actual)

## Conditions studied

- Diarrhea

## Interventions

- **DRUG:** lanreotide (Autogel formulation)

## Key facts

- **NCT ID:** NCT00891371
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-08
- **Final completion:** 2013-08
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891371, "Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00891371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*